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studies suggest that it is expressed and functionally impor-
tant also in blood vessels, not only because haematopoietic
cells can incorporate in the vascular wall but also because
Orai1 is expressed and functional in vascular smooth muscle
cells and endothelial cells. This article summarises the aris-
ing observations in this new area of vascular research and
debates underlying issues and challenges for future inves-
tigations. The primary focus is on vascular smooth muscle
cells and endothelial cells. Specific topics include Orai1
expression; Orai1 roles in store-operated calcium entry and
ionic currents of store-depleted cells; blockade of Orai1-
related signals by Synta 66 and other pharmacology; acti-
vation or regulation of Orai1-related signals by physiologi-
cal substances and compartments; stromal interaction
molecules and the relationship of Orai1 to other ion chan-
nels, transporters and pumps; transient receptor potential
canonical channels and their contribution to store-operated
calcium entry; roles of Orai1 in vascular tone, remodelling,
thrombus formation and inflammation; and Orai2 and Orai3.
Overall, the observations suggest the existence of an addi-
tional, previously unrecognised, calcium channel of the
vascular wall that is functionally important particularly in
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Introduction
In 2006, seminal work identified membrane proteins that
were named Orais, after the Greek keepers of Heaven’s gate
[20, 32, 33, 75, 76, 97, 108, 109]. An alternative name is
CRACM but this is less commonly used. The proteins
emerged through a study of severe combined immune defi-
ciency (SCID), which is caused by a defect in Ca
2+ entry of
T cells [32]. A mutation in the Orai1 gene underlies this
defect [33].
In predicted structure, the Orais resemble members of the
extensively studied tetraspanin proteins. The Orais do not
resemble other known ion pore-forming subunits of ion
channels, although similarity to the regulatory (non-pore-
forming) γ-subunit of voltage-gated Ca
2+ channels has been
suggested [99]. Nevertheless, several studies now indicate
that Orais cluster together to form a Ca
2+ selectivity filter
and thus can be considered to be bona fide Ca
2+ channels
[108, 109]. Other tetraspanins or tetraspanin-like proteins
are not known to form Ca
2+ channels, although MS4A12 (a
sequence homologue of CD20) is a candidate [53]. At the
present time, there are no crystal structures for Orais, but
they are suggested to have four membrane spanning
segments, two extracellular loops and intracellular amino
and carboxy termini [66, 109]. A pear-drop structure about
15 nm in height and 9.5 nm in width is indicated by electron
microscopy [66]. Residency in the plasma membrane occurs
but localisation to other compartments is not excluded. The
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Abstract Orai1 was discovered in T cells as a calcium-
selective channel that is activated by store depletion. Recent
remodelling but probably also in certain vasoconstrictor
contexts.Orais have molecular masses of about 30 kDa and these may
be substantially increased by glycosylation.
Against the immunological backdrop of Orai1’s discov-
ery, it was initially surprising that Orai1 is widely expressed
but many studies now suggest expression of Orai1 not only
in cells of the haematopoietic lineage [32] but also in other
cell types that include vascular smooth muscle and endothe-
lial cells (see below). The observations have started to
provide important new insight into the Ca
2+-handling capa-
bilities of these cell types and shed light on the enigmatic
process of store-operated Ca
2+ entry (SOCE), which was
first suggested in vascular smooth muscle 31 years ago [21].
Orai2 and Orai3 may also be relevant to blood vessels but
available information on them is limited (see below).
This review summarises and debates evidence that Orais
are important in blood vessels, with particular focus on two
primary cell types of the vascular wall: vascular smooth
muscle cells and endothelial cells in either their quiescent
phenotypes or proliferating and migrating phenotypes. The
quiescent phenotypes are especially relevant to the control
of contractile tone and its regulation by endothelial factors,
impacting on whole body phenomena such as peripheral
resistance and tissue perfusion. The proliferating and mi-
grating phenotypes are especially relevant to vascular de-
velopment and the remodelling events of physiology and
pathology that include neointimal hyperplasia, angiogenesis
and endothelial repair.
Expression of Orai1 mRNA and protein
Most of the RT-PCR, western blotting and immunocyto-
chemical evidence for expression of Orai1 in vascular cells
has arisen from studies of cultured vascular smooth muscle
cells, which are migrating and proliferating but not contrac-
tile. Orai1 mRNA and protein were demonstrated in this
type of cell derived from human aorta or saphenous vein [8,
13, 59], rat aorta [15, 77], rat coronary artery [29] or mouse
pulmonary artery [70]. Orai1 was also detected in the A10
cell line [24], which is a model system for proliferating
vascular smooth muscle cells. Orai1 protein was found to
be almost undetectable in human aorta homogenate [13]o r
freshly isolated rat aorta vascular smooth muscle cells [77].
Orai1 protein was, however, detected in pig coronary artery
[31] and rat carotid artery [107], and weak staining was
reported in the smooth muscle cells of arterial sections [15,
107]. Orai1 protein was detected in rat coronary artery that
had been organ-cultured for 48 h [29]. In vivo injury of
arteries by physical or metabolic insult enabled clear detec-
tion of endogenous Orai1 in vascular smooth muscle cells of
intact arteries [15, 31, 107]. Furthermore, a 24-h treatment
of cultured vascular smooth muscle cells with platelet-
derived growth factor (PDGF) led to enhanced Orai1 protein
expression [72]. Therefore, the available evidence suggests
relatively low Orai1 expression in native contractile vascu-
lar smooth muscle cells and higher expression in proliferat-
ing and migrating vascular smooth muscle cells, whether the
phenotype is induced in vitro or in vivo. There is less
RT-PCR or biochemical evidence for expression of Orai1
in endothelial cells. Nevertheless, Orai1 mRNA and protein
were detected in human umbilical vein endothelial cells
(HUVECs) [1, 57, 88], the HUVEC adenocarcinoma EA.
hy926 cell line [6], human lung microvessel endothelial
cells [88], rat pulmonary microvascular endothelial cells
[81] and immortalised mouse lung endothelial cells [88].
Orai1 mRNA was also detected in endothelial colony-
forming cells [80].
Positive role of Orai1 in SOCE
A common experimental protocol applied to isolated cells is
the short-term depletion of intracellular Ca
2+ stores in the
absence of extracellular Ca
2+, for example through applica-
tion of physiological agonists that cause IP3-induced Ca
2+
release or application of pharmacological substances that
inhibit sarcoplasmic/endoplasmic reticulum Ca
2+ ATPase
(SERCA, the pump mechanism that normally loads Ca
2+
into the stores). Extracellular Ca
2+ is then added back to
observe Ca
2+ entry, which is detected by an intracellular
Ca
2+ indicator. The detected rise in intracellular Ca
2+ is
often called the Ca
2+ add-back response. The response is
considerably larger in cells that have undergone store de-
pletion, and it is primarily this observation that has led to the
suggestion that store depletion triggers the opening or inser-
tion of additional Ca
2+ entry channels in the plasma mem-
brane. The additional Ca
2+ entry is often referred to as
SOCE (or capacitative Ca
2+ entry) and the channels as
store-operated channels (SOCs) [95]. The experimental pro-
tocol is simple and the SOCE is striking but the complexi-
ties of the underlying biology are considerable, not least
because such store depletion evokes radical changes in
intracellular Ca
2+ handling and store depletion itself is one
of the classical triggers for endoplasmic reticulum (ER)
stress and the associated unfolded protein response [27].
Nevertheless, studies of SOCE have yielded critical under-
standing of mechanisms controlling Ca
2+ in a wide variety
of cell types. Orai1 is an important element.
In cultured vascular smooth muscle cells and endothelial
cells, there is SOCE. Inhibition of Orai1 expression has
been found to reduce this SOCE [1, 8, 29, 57, 59, 64, 70,
77, 103]. The degree of reduction has varied from study to
study but most reports agree that Orai1 plays a positive role
in SOCE of these vascular cells. The studies have depended
on the use of short-interfering (si) RNA [48] to suppress
Orai1 expression and thus relied on the specificity of this
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have been used and the role of Orai1 has been confirmed by
expression of a dominant-negative mutant of Orai1 [57, 59,
64]. Furthermore, over-expression of wild-type Orai1 has
been shown to rescue SOCE after Orai1 knock-down by
siRNA [59]. There have been suggestions of a critical (i.e.
essential) role for Orai1 in SOCE. Evidence for such sugges-
tions comes from studies of T cells from SCID patients or
micecarryinggeneticdisruptionoftheOrai1gene,butevenin
these studies residual SOCE can be observed [96]. Studies of
vascular smooth muscle cells and endothelial cells in the
complete absence of Orai1 have yet to be reported. Studies
of cells from gene-disrupted Orai1−/− mice are complicated
by immune deficiency and perinatal lethality [47].
A study of immortalised mouse endothelial cells found
no effect on SOCE of Orai1 siRNA or over-expression of
wild-type Orai1 or dominant-negative mutant Orai1 [88]. In
human lung microvessel endothelial cells, Orai1 siRNA
appeared to reduce the initial peak SOCE but a statistically
significant effect was not identified [88]. The investigators
suggested that, although Orai1 is expressed, it does not
contribute to SOCE in these microvascular-derived endo-
thelial cell types.
Positive roles of Orai1 in ionic current of store-depleted
cells
If SOCE does indeed result from net inward movement
of Ca
2+ across the plasma membrane, there must be an
inward ionic current and it may be possible to detect it
by whole-cell patch-clamp electrophysiology. Patch-
clamp also has the ability to control the membrane po-
tential and so minimise changes in membrane potential
that complicate interpretation of results from intracellular
Ca
2+ indicator studies. Furthermore, the intracellular di-
alysis of cells with Ca
2+ buffers, delivered by the patch-
clamp pipette, can avoid or minimise intracellular Ca
2+
rises that stimulate ion channels.
Patch-clamp studies of blood cells have, for many years,
consistently revealed a distinctive inward ionic current un-
der conditions that cause store depletion [75]. The current is
referred to as calcium-release-activated Ca
2+ (CRAC) cur-
rent, or I-CRAC, and is quite well established as an electro-
physiological correlate of SOCE. It is characterised by its
Ca
2+ selectivity, inward rectification and very small ampli-
tude (a few picoamperes). Single channel currents are cal-
culated to be well below the resolving power of patch-clamp
technology. Orai1 clearly plays a major role in I-CRAC and
is considered to arrange as a tetramer to form the ion pore of
the underlying Ca
2+ channels [66, 109]. It is important to
note that the experimental conditions for recording I-CRAC
are largely standardised and non-physiological [1, 14].
Some of these conditions have been necessary to distinguish
the current from other signals. Features of the conditions
include the high concentration of extracellular Ca
2+ (usually
10 or 20 mM) and hyper-tonicity of the extracellular medi-
um. A Na
+-mediated ‘I-CRAC’ is often recorded in the
complete absence of extracellular Ca
2+ (divalent cation free,
DVF, medium). Another common condition is a high con-
centration of Ca
2+ buffer in the intracellular (patch pipette)
solution (e.g. 20 mM BAPTA). The buffer serves the pur-
poses of depleting the stores and suppressing cytosolic Ca
2+
rises but it also lowers the basal cytosolic Ca
2+ concentra-
tion, indiscriminately inactivating Ca
2+-dependent process-
es. It is less common that I-CRAC is shown to be activated
by a SERCA inhibitor when intracellular Ca
2+ is buffered at
the physiological concentration of about 100 nM.
There has been more difficulty recording I-CRAC or
I-CRAC-like signals from vascular smooth muscle cells
or endothelial cells [1, 37, 40, 57, 77, 98]. All of these
recordings have been made from cell lines or low pas-
sage cells after primary culture. Therefore, the cells have
been in proliferating and migrating phenotypes. The first
report showing an I-CRAC-like signal was based on
HUVECs [1]. The current amplitude was about five
times smaller than that of immune cells, which is close
to the resolving power of whole-cell patch-clamp. It was
most convincingly shown in DVF medium and using
20 mM BAPTA in the patch pipette. It exhibited charac-
teristics similar to those of the Na
+ ‘I-CRAC’ of blood
cells. It was diminished by Orai1 siRNA. Similar record-
ings were made from A7r5 and cultured rat aorta vascular
smooth muscle cells [77, 98]. Similar reduction by Orai1
siRNAwas observed [77].
Although investigation of the relationship to Orai1 was
not shown, patch-clamp studies to seek out and determine
the properties of I-CRAC were reported also in studies of
EA.hy926 cells [40]. Perforated patch whole-cell recording
was used in order to minimise the modification of the
intracellular milieu. I-CRAC-like current was detected in
response to SERCA inhibition in the presence of extracel-
lular 10 mM Ba
2+ and 2 mM Ca
2+, or 0.1 mM Ba
2+ and
10 mM Ca
2+. The current was inwardly rectifying and small
but showed a reversal potential near −11 mV [40]. Such a
reversal potential, compared with the positive value de-
scribed for I-CRAC in blood cells, led the authors to suggest
that the current had less Ca
2+ selectivity than I-CRAC of
blood cells.
I-CRAC is not the only ionic current activated by store
depletion. Various studies of proliferating or contractile
vascular smooth muscle cells or endothelial cells have
shown a non-selective cationic current [12, 31, 60, 63, 64,
79, 89, 94, 101, 103]. The characteristics of currents vary
between studies and standardised recording conditions have
not been used but the current–voltage relationship (I–V)
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approaching 0 mV, and current observed with or without
strong buffering of intracellular Ca
2+. A recent report
showed that Orai1 siRNA strongly suppressed the current
in mouse aorta smooth muscle cells [103]. There is a similar
current in proliferating human saphenous vein vascular
smooth muscle cells [60] and it too is suppression by Orai1
siRNA [58]. The current is hard to reconcile with the prop-
erties of Orai1 Ca
2+ channels as defined by I-CRAC. The
phenomenon remains an on-going matter of investigation
but, in part, it is explained by transient receptor potential
(TRP) canonical channels (see below). Apparently similar
non-selective cationic currents evoked by store depletion
have been reported in blood cells and skeletal muscle [86,
87]. Studies of EA.hy926 cells have emphasised the com-
plication that can arise from Na
+–Ca
2+ exchanger current
[40] but this is not the explanation for the non-selective
cationic current.
Blockade of Orai1-related signals by Synta 66
and other pharmacology
An intriguing pharmacological agent in relation to Orai1
Ca
2+ channels, SOCE and I-CRAC is the chemical that is
referred to as Synta 66 (3-fluoropyridine-4-carboxylic acid
(2′,5′-dimethoxybiphenyl-4-yl)amide). In addition to patent
information (WO 2005/009954), the effects of Synta 66 on
SOCE and I-CRAC in basophilic leukaemia and Jurkat T
cells have been reported [26, 71]. Synta 66 does not affect
plasma membrane Ca
2+ ATPase, inward rectifier K
+ current,
hippocampal synaptic transmission, or radio-ligand binding
to a range of receptors and ion channels including the L-type
Ca
2+ channel [26, 71].
Synta 66 is also an inhibitor of SOCE in proliferating
vascular smooth muscle cells and endothelial cells [57, 59].
Strikingly, the IC50 is ~25 nM which is about two orders of
magnitude better than for blood cells [57, 59]. The speed of
block is relatively rapid (occurring in less than 10 s). Selec-
tivity of Synta 66 was also suggested because there was no
effect of 5 μM Synta 66 on Ca
2+ release evoked by ATP or
growth factors [57, 59]. There was no effect on Ca
2+ entry
through transient receptor potential canonical (TRPC1, 5, 6)
or vanilloid (TRPV4) channels, each activated without store
depletion. There was also no effect on contraction of aorta
evoked by an α1-adrenoceptor agonist, suggesting no effect
of Synta 66 on the array of systems underlying this complex
contractile phenomenon [59]. There was no effect on cell
viability [57]. Synta 66 appears, therefore, to be an easy-to-
use, selective and potent inhibitor of SOCE. It is not cur-
rently available from a commercial supplier but may be
obtained as a gift from a pharmaceutical company or syn-
thesised relatively easily by a medicinal chemist.
The mechanism of action of Synta 66 on SOCE is un-
known. It may act as an ion pore blocker of Orai1 Ca
2+
channels, perhaps by binding directly to Orai1. However,
evidence to support such a hypothesis is not reported. In-
deed, the common roles of Orai1 in SOCE of vascular
smooth muscle cells, endothelial cells and blood cells, set
against the differential potencies of Synta 66 in these cell
types (as text above), argue against Orai1 as the target
protein. Nevertheless, if Orai1 is not the target protein, we
do not yet have another clear candidate as the target. It is
conceivable that it acts in some way to modify the coupling
between depleted stores and Orai1 channels but this is not
exhibited as an effect on the clustering of the store Ca
2+
sensor [59]. It is also not exhibited as inhibition of non-
selective cationic current evoked by store depletion [59].
Other inhibitors of vascular SOCE include 2-
aminoethoxydiphenyl borate (2-APB), 4-methyl-4′-[3,5-bis
(trifluoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-5-car-
boxanilide (BTP-2, Pyr2, or YM-58483) and lanthanides
[35, 67, 77, 80]. These agents are also commonly described
as TRPC channel inhibitors. Additional inhibitors of SOCE
are listed by Flemming et al. [35] or include diethylstilbes-
trol [105], non-steroidal anti-inflammatory drugs [67], and
5-nitro-2-(3-phenylpropylamino)-benzoic acid [37]. It is not
clear if any of these agents act directly as channel blockers
and there is evidence that some of the agents, such as non-
steroidal anti-inflammatory drugs, act indirectly [67].
The greater potency of Synta 66 on SOCE of vascular
smooth muscle and endothelial cells (compared with blood
cells) suggests a difference in the molecular mechanism of
SOCE in these cells, even though the SOCE in all cases
shows partial or strong dependence on Orai1. Different
sensitivity to 2-APB [77] adds weight to this suggestion.
Weaker Ca
2+ selectivity of I-CRAC in endothelial cells has
also been suggested to indicate a different molecular basis
[40]. The identity of such distinction is not yet reported.
Activation or regulation of Orai1-related signals
by physiological substances and compartments
The studies described above refer to Ca
2+ entry evoked by
non-physiological stimuli. This is not to infer that they lack
physiological relevance but it is necessary to consider if or
when physiological stimuli can activate them. This is espe-
cially important because store depletion is a signal that leads
to cell apoptosis and because physiological agonists can
evoke Ca
2+ release without causing significant store deple-
tion, as demonstrated, for example, by simultaneous meas-
urements of cytosolic and ER Ca
2+ in endothelial cell lines
[40, 65]. However, many investigators have applied physi-
ological agonists to cells in the absence of extracellular Ca
2+
and then used the Ca
2+ add-back protocol to observe Ca
2+
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2+
release and Ca
2+ entry, it is weakened by being a store
depletion protocol (because the stores cannot refill after
the Ca
2+ release event). The experimental difficulty in-
volved in avoiding inadvertent store depletion has been
emphasised [40]. Consequently, there is only limited informa-
tion about which physiological agonists activate Ca
2+ entry
that depends on Orai1 in the continuous presence of extracel-
lular Ca
2+ and without store depletion. Two substances that
activate the channels in this situation are the important growth
factors PDGF and vascular endothelial growth factor (VEGF)
[57, 59]. ATP activates Synta 66-sensitive Ca
2+ entry in the
continuous presence of extracellular Ca
2+ but it was not
reported if this effect was inhibited by Orai1 siRNA [59].
Strikingly, Ca
2+ entry stimulated by lysophosphatidylcholine
(0.3 μM) was suppressed by Orai1 siRNA even though the
lysophosphatidylcholine did not evoke Ca
2+ release, suggest-
ing Ca
2+-release-independent activation of Orai1 channels in
vascular smooth muscle cells [29].
Intriguing stimulation of SOCE-like Ca
2+ entry by
sphingosine-1-phosphate has been described in vascular
smooth muscle cells [50]. While sphingosine-1-phosphate
evoked Ca
2+ release via G protein-coupled receptors, the
SOCE-like signal occurred independently of sphingosine-1-
phosphate receptors and was mimicked by intracellular
sphingosine-1-phosphate [50]. The SOCE-like signal was
not, however, shown to be Orai1-dependent.
Localisation of Orai1 to membrane density fractions con-
taining caveolin-1 was described in studies of pulmonary
microvascular endothelial cells, suggesting compartmental-
isation of Orai1-dependent Ca
2+ signalling [81]. The frac-
tions also contained the Ca
2+-regulated adenylyl cyclase 6.
A submembrane compartment for regulation of filamin A by
Ca
2+ and cyclic AMP was suggested to play a role in the
control of endothelial cell shape [81].
Stromal interactionmolecules(STIMs) and the relationship
of Orai1 to other ion channels, transporters and pumps
A year before the discovery of Orai1 came the discovery of
the relevance of stromal interaction molecules 1 and 2
(STIM1 and STIM2) to SOCE [20, 78]. STIMs are single-
pass membrane-spanning proteins that are larger than Orais
(STIM1 has a predicted mass of 75 kDa). Unlike Orais,
STIMs were initially identified independently of the Ca
2+
signalling field as glycosylated phosphoproteins located to
the cell surface. Although subsequent studies confirmed
STIM1 localisation in the plasma membrane, its relevance to
SOCEisnowmostcommonlydescribedintermsofSTIM1as
a protein of the ER membrane [20]. Prior to store depletion,
STIM1is thought to directly bind the microtubule-plus-end-
trackingprotein EB1, forming comet-like accumulations [44].
STIM1 is considered to be the primary sensor of the Ca
2+
content of the ER (or sarcoplasmic reticulum), detecting store
depletion and relaying this information to Orai1 channels in
the surface membrane through a complex process of confor-
mational change, redistribution, clustering and physical asso-
ciation with Orai1 that clusters Orai1 proteins and activates
them to enable Ca
2+ entry [20]. STIM2 is also thought to play
such a role but with a different Ca
2+ sensitivity [20].
STIM1 and STIM2 are expressed in vascular smooth
muscle cells and endothelial cells. Knock-down of the ex-
pression of either type of STIM suppresses SOCE, with
STIM1 knock-down usually showing the greater effect
[60, 62]. Detailed studies on other cell types have demon-
strated Orai1 and STIM1 interaction [76, 104]. Less detailed
studies have provided data in support of the interaction and
co-localisation of endogenous Orai1 and STIM1 in vascular
smooth muscle cells [17, 70]. Investigation of endogenous
STIM1 has also revealed constitutive localisation to the
plasma membrane and surface exposure of the amino termi-
nus in vascular smooth muscle cells [60]. This surface
STIM1 localisation is not altered by store depletion [60].
Although ER localisation of STIM1 has been suggested in
vascular smooth muscle cells [92], it was not definitely
identified as ER STIM1 and extensive investigation of this
STIM1 has yet to be reported. A challenge with studies of
STIM1 localisation is that protein tags attached to the
STIM1 molecule prevent its surface localisation, tending
to favour ER localisation of the STIM1 [49].
STIM1 does not only interact with Orai1 channels, it also
binds ion channels that include TRPC1 and the voltage-
gated Ca
2+ channel subunit CaV1.2 [98, 106]. Biochemical
interaction of endogenousS T I M 1a n dT R P C 1h a sb e e n
demonstrated in vascular smooth muscle cells, but there is
only partial co-localisation of the proteins, suggesting that
they share a function but also have discrete functions [60].
Studies in over-expression systems have suggested that
STIM1 activates TRPC1 channels following store depletion
[106]. In endothelial cells, store depletion evoked forward
trafficking of TRPC1 and TRPV4 to the surface membrane
and this effect was partially inhibited by STIM1 siRNA [63,
64]. Studies in the A7r5 vascular smooth muscle cell line
have suggested that STIM1 interaction inhibits CaV1.2,
leading to suppression of voltage-dependent Ca
2+ entry in
store-depleted cells and a reciprocal relationship with SOCE
[98].ClusteringofSTIM1andOrai1withNa
+–Ca
2+exchang-
er, plasma membrane Ca
2+ ATPase and SERCA is suggested
from studies of other cell types, indicating that STIM1 has a
broad coordinating role for Ca
2+ transport mechanisms and
emphasising that its function is not restricted to Orai1 interac-
tion [54]. Specifically in proliferating vascular smooth muscle
cells, co-localisation of Orai1 and Na
+–Ca
2+ exchanger
(NCX1) was observed and Orai1 siRNA suppressed NCX1
expression as well as Orai1 expression [8]. Plasma membrane
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2+ATPase(PMCA1)expressionwasalsosuppressed.Na
+–
Ca
2+ exchange did not, however, influence SOCE [8]. SER-
CA2a, but not SERCA2b, expression was found to inhibit
interaction between Orai1 and STIM1 [17]. Because SER-
CA2a was down-regulated when vascular smooth muscle
cells switched to the proliferating phenotype, it was suggested
that loss of this inhibitory effect of SERCA2a may contribute
tothe explanation for the large SOCE inproliferating vascular
smooth muscle cells and the associated translocation of nu-
clear factor of activated Tcells to the nucleus [17].
TRPC channels and SOCE
It is suggested by the above text that Orai1 Ca
2+ channels
contribute to SOCE in vascular smooth muscle cells and
endothelial cells. There are, however, also reports suggest-
ing that TRPC channels contribute to SOCE in these cells
[19, 36, 55, 60, 63, 64, 69, 82, 88–91, 93, 100, 101].
Although crystal structures are lacking for Orai and TRPC
channels, there are clear suggestions that Orai and TRPC
proteins are structurally unrelated. Moreover, the Orais
mostly generate small Ca
2+-selective and inwardly rectify-
ing channels, whereas TRPC channels generate larger mixed
cationic Ca
2+- and Na
+-permeable channels with complex
rectification that includes substantial outward current. These
two channel types are unlikely to participate in generating a
common ion pore (i.e. they are almost certainly distinct ion
channels). Furthermore, while Orai1 channels have mostly
been associated with activation by store depletion, there is
plenty of evidence that TRPC channels do not require store
depletion in order to be activated and may often be activated
even without concomitant Ca
2+ release [2, 3, 10, 102]. The
TRPC channels are not addressed in detail here, but a brief
discussion of the relation to SOCE is included because the
suggestion that they also contribute to SOCE is controver-
sial, because the physiological significance of SOCE should
be addressed, and because there is indication of an intimate
relationship between Orai and TRPC channels, which
remains poorly understood.
It may be that both Orai1 and TRPC channels contribute
to vascular SOCE. This would explain why some studies
show partial suppression of SOCE by Orai1 or TRPC
siRNA [59, 60]. Different (apparently conflicting) results
from different research groups [1, 46, 64, 88, 91] may be
explained by variable relative contributions of Orai1 and
TRPC depending on the exact type of cell, the condition of
the cells, the culture medium, the substrate, the precise
details of the experimental protocol, etc. Shared contribution
to SOCE would be consistent with the substantial evidence
that both types of channel interact with STIM1 [76, 106] and
that STIM1 redistribution in response to store depletion has
major implications for a range of Ca
2+ transport proteins
[54]. One study of cultured vascular smooth muscle cells
suggested that Orai1 determines the first (transient) phase of
SOCE, and TRPC1 the sustained SOCE [69, 70]. A study of
EA.hy926 cells suggested a time-independent and distinct
TRPC3 component of SOCE that depended on phospholi-
pase C activity [6]. These studies suggest two distinct chan-
nels of SOCE (Orai and TRPC), but a study of HUVECs has
suggested overlap and a shared Orai–TRP channel arrange-
ment [64].
Important in this discussion is the definition of SOCE
which, in practice, is a Ca
2+ entry phenomenon observed
under non-physiological conditions (see above). From a
biological perspective, however, many investigators have
been using SOCE as a means to understand the physiolog-
ical mechanism by which stores refill following IP3-evoked
Ca
2+ release. The refilling process is expected to be trig-
gered by the SOCE protocol but the protocol also has other
consequences that probably do not occur, or are less prom-
inent, when a physiological agonist evokes Ca
2+ release
under physiological conditions at a physiological concen-
tration. One of these consequences is ER stress. Given the
emerging evidence of TRPC activation by stress factors [3,
10, 28, 68], it can be anticipated that TRPC activity may be
increased as a result of the SOCE (ER stress?) protocol.
Potentially, dependence of SOCE on Ca
2+-independent
phospholipase A2 [29, 85, 103] reflects such a stress rela-
tionship because activation of this phospholipase is one of
the factors involved in TRPC channel activation [4], Orai1
activation [29] and the ER stress response [56].
Another method for investigating the physiological refill-
ing process has been the I-CRAC protocol. In many studies,
however, this too is non-physiological (see above). Further-
more, the protocol is designed to isolate and highlight I-
CRAC. It is quite possible that the intricate Ca
2+ and Ca
2+
sensor dependencies of TRPC channels [16, 51, 74, 82, 83]
lead them to be suppressed or otherwise modified by the I-
CRAC recording protocol, which may explain why there
has been little or no resemblance of I-CRAC to ionic cur-
rents generated by over-expressed TRPC channels. Intrigu-
ingly, however, a study of freshly isolated contractile
vascular smooth muscle cells showed a relatively linear
I–V in I-CRAC recording conditions and strong dependence
on TRPC1 [82].
In summary, it is suggested that (1) Orai1 and TRPC
form distinct ion channels that do not heteromultimerise
with each other; (2) Orai1 and TRPC can both contribute
to the SOCE phenomenon in vascular smooth muscle
cells or endothelial cells; (3) Orai1 and TRPC interact
physically with STIM1 and interplay with other Ca
2+-
handling proteins such as Na
+–Ca
2+ exchanger; (4) Orai1
is the molecular basis of the I-CRAC Ca
2+-selectivity
filter and TRPCs do not contribute to it; (5) I-CRAC is
not the only ionic current activated by store depletion;
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dently of store depletion or Ca
2+ release.
Elucidation of the physiological mechanism by which
stores refill following IP3-evoked Ca
2+ release is one of
the goals of the research. What we do know is that the
Ca
2+-ATPases of the stores, and especially SERCAs, are
the refilling mechanism at the level of the stores and that
they refill the stores using free Ca
2+ from the cytosol.
Therefore, in principle, any Ca
2+ entry channel that contrib-
utes to the cytosolic free Ca
2+ concentration near SERCA
can contribute to store refilling; even Na
+ entry acting
indirectly via Na
+–Ca
2+ exchange can contribute. There is
evidence that several types of Ca
2+ entry channel can con-
tribute in this way. The fascination in the field, however, has
been that there might be a particular type of Ca
2+ entry
channel that is particularly specialised for providing Ca
2+
to SERCA and in a restricted subcellular compartment. This
specialised channel would seem to be the I-CRAC channel
(i.e. the Orai1 channel). Evidence is pointing to the conclu-
sion that such a specialised channel is a core feature across
many cell types, including vascular smooth muscle cells and
endothelial cells. Indeed, the original pioneering study of
store refilling in vascular smooth muscle argued for a
privileged Ca
2+ entry mechanism that directly fills the stores
from the extracellular medium with minimal impact on the
globalcytosolic Ca
2+concentration [21].Nevertheless,itdoes
not follow that this privileged mechanism is the only Ca
2+
entry mechanism providing extracellular Ca
2+ for store refill-
ing or that it is the only Ca
2+ entry channel activated by store
depletion. It seems unlikely that cells would have evolved
dependence on a single mechanism for store refilling when
store depletion is a critical event leading to apoptosis.
Orai1 in vascular tone (contractile phenotype)
After a period of depletion of Ca
2+ stores in Ca
2+-free
extracellular medium, Ca
2+ add-back was found to cause a
contractile response in aorta that was larger in stroke-prone
spontaneously hypertensive rats [38]. Delivery of anti-Orai1
antibody by the Chariot technique suppressed the contrac-
tion [38]. These data suggest that functional Orai1 channels
exist in contractile vascular smooth muscle cells of the aorta.
Superficially, the observation conflicts with the finding that
Synta 66 had no effect on α1-adrenoceptor-mediated contrac-
tion of mouse aorta [59]. The Synta 66 result is, however,
consistent with the study of rat aorta which showed that SOCE
inhibitors were ineffective when the Ca
2+ add-back response
was not preceded by exposure to a SERCA inhibitor in nor-
motensive animals [38]. Therefore, the preliminary conclusion
from these studies is that SOCE is not particularly important in
contractile function of physiological aorta unless there is sub-
stantial store depletion. The suggestion is reminiscent of prior
studies, for example on cerebral arterioles, which have also
suggested that SOCE generates an intracellular Ca
2+ elevation
that is not well coupled to contraction [34]. However, investi-
gation of rat coronary artery has shown that contractions
evoked by urotensin-II, the α1-adrenoceptor agonist phenyl-
ephrine or lysophosphatidylcholine are suppressed in arterial
segments cultured for 48 h after Orai1 siRNA delivery [29].
The effects were observed in the continuous presence of ex-
tracellular Ca
2+, and therefore, they suggest that Orai1 chan-
nels are important in physiological contractile responses of this
artery. A note of caution, however, is that previous work on
basilar artery suggested that SOCE had no effect on contrac-
tion of freshly isolated artery but strong effect on contraction
after organ culture of the artery for 72 h [11, 12]. Although
vessels can remain contractile after periods of culture, early
remodelling events are likely to have taken place (see below).
Further studies would be valuable on the relevance of Orai1 to
contractile function in various blood vessels and in relation to
endothelium-dependent vasodilatation.
Orai1 in vascular remodelling (migrating
and proliferating phenotypes)
Several studies have found that expression of Orai1 mRNA
and protein are up-regulated when vascular smooth muscle
cells undergo their switch from the contractile to the non-
contractile (migrating and proliferating) phenotype (see
above). It has also been observed that SOCE is larger in
proliferating vascular smooth muscle cells [41, 42]a n d
many of the studies of SOCE and Orai1 have focused on
vascular smooth muscle cells in culture, which causes rapid
switching to the non-contractile phenotype. Moreover, inhi-
bition of migration has been observed after Orai1 knock-
down by siRNA, suggesting an important role of Orai1 in
the non-contractile phenotype [59, 77]. An inhibitory effect
of Orai1 siRNA on cell number of rat aorta vascular smooth
muscle cells was reported [77], but the effect was relatively
small and the number of human saphenous vein vascular
smooth muscle cells was unaffected at the same 48-h time
point, suggesting a preferential effect on migration [59]. In
studies of human aorta vascular smooth muscle cells, there
was a reduction in cell number at the later time point of 77 h
[8]. Similarly, Synta 66 inhibited migration but not the
number of vascular smooth muscle cells [59]. Further sup-
port for a role of Orai1 in the migrating phenotype came
from the finding that Orai1 siRNA markedly inhibited the
sustained elevation of intracellular Ca
2+ evoked by PDGF in
the continuous presence of extracellular Ca
2+ [59]; this
finding is important because PDGF is the primary growth
factor driving smooth muscle cell recruitment during vascu-
lar development and pathological remodelling [52]. In vivo
studies have found that Orai1 knock-down strongly reduces
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the effect of STIM1 knock-down [7, 45]. Similarly, STIM1
knock-down suppresses vascular smooth muscle cell migra-
tion in vitro [60]. Collectively, these findings suggest that
Orai1 channels and SOCE play key positive roles in en-
abling efficient vascular smooth muscle cell remodelling,
working with a range of other ion channels that include
TRPC1 and KV1.3 potassium channel [9, 23, 25, 55].
Endothelial cells also remodel using a phenotype that
displays migrating and proliferating properties. Knock-
down of Orai1 by siRNA inhibits the migration [57] and
proliferation [1] of HUVECs. It also markedly inhibits the
sustained elevation of intracellular Ca
2+ evoked by VEGF
[57], the primary growth factor driving endothelial cell
migration and endothelial remodelling events such as angio-
genesis[73].Invitrotubeformation,whichmimicsfeaturesof
angiogenesis, was inhibited by Orai1 siRNA or dominant-
negative mutant Orai1 [57]. Exogenous wild-type Orai1 res-
cued the tube formation after Orai1 knock-down by siRNA
[57]. Synta 66 inhibited endothelial cell migration and in vitro
tube formation and suppressed angiogenesis in vivo in the
chick chorioallantoic membrane [57]. Similarly, suppression
of STIM1 inhibited angiogenesis in vivo [22]. A study of EA.
hy926 cells,bycontrast, found noeffectofOrai1 siRNAonin
vitro endothelial tube formation, a difference the authors
suggest may have been due to the absence, or low concentra-
tion of, VEGF in their studies [5]. A reduction in EA.hy926
cell proliferation by Orai1 siRNAwas observed [5], similar to
findings in HUVECs [1]. Proliferation and tubulogenesis of
endothelialcolonyformingcellsinthe presenceofVEGFwas
inhibited by BTP-2 [30]. Overall, the findings suggest that
Orai1 channels and SOCE are important in endothelial cell
proliferation, VEGF signalling, VEGF-driven endothelial cell
migration and VEGF-driven angiogenesis.
Orai1 in thrombus and inflammation
This review focuses on two dominant cell types of the
vascular wall but it should be borne in mind that Orai1 is
also expressed in blood cells (T cells, monocytes, platelets,
etc.) which can interact with and integrate in the vascular
wall as part of inflammatory and thrombotic events. Numer-
ous studies suggest the importance of Orai1 channels in
thrombus formation and inflammation [18, 32, 39].
Orai2 and Orai3
Orai2 and Orai3 mRNAs are also detected in vascular
smooth muscle cells and endothelial cells [1, 8, 59, 80],
showing either substantial abundances that are greater than
those of Orai1 mRNA [8, 59] or minimal abundance [88].
Orai2 and Orai3 proteins have also been detected [13, 17,
24, 77, 88]. Orai2 and Orai3 were up-regulated in prolifer-
ating compared with contractile vascular smooth muscle
cells [8]. Knock-downs of Orai2, Orai3 or Orai2 and Orai3
by siRNAs have shown no effect on SOCE or basal cyto-
solic Ca
2+ in proliferating vascular smooth muscle cells [8,
15, 59, 77] even though over-expression studies in the
human embryonic kidney (HEK) 293 cell line have suggested
that Orai2 or Orai3 is capable of reconstituting an I-CRAC
[61]. There was also no effect of Orai2 or Orai3 siRNA on
vascularsmoothmusclecell migration orproliferation [8, 15].
Intriguing studies of an endogenous arachidonate-regulated
Ca
2+ (ARC) channel in HEK 293 cells have suggested that
this channel is formed from a pentameric arrangement of
Orai1 with Orai3 [84]. It is not reported if such a channel is
relevant to the vasculature.
Conclusions and future challenges
The evidence points to Orai1 as a novel Ca
2+ channel of
blood vessels. The strongest evidence for expression and
roles of Orai1 in the vasculature is in remodelling events
that relate to neointimal hyperplasia and angiogenesis. Orai1
can play significant positive roles in migrating and prolifer-
ating behaviours of vascular smooth muscle and endothelial
cells, all of which are important in events such as neointimal
hyperplasia and angiogenesis. There is less evidence for the
expression and roles of Orai1 in the contractile state of
blood vessels but function is indicated and may be important
in specific vessels under certain conditions. In both the
remodelling and contractile contexts, there is need for more
information on the expression and functional relevance of
endogenous Orai1 channels especially in freshly isolated
cells and tissues and, in vivo, in animals under physiological
and pathological conditions.
A fundamental implication from Orai1’s discovery is that
it represents a long-sought, privileged and widespread
mechanism for refilling of depleted Ca
2+ stores. It would
seem to be true that Orai1 provides such a mechanism, but
strengths of the argument depend substantially on principles
developed from studies of cell types other than vascular
smooth muscle and endothelial cells or from over-
expression approaches in cell lines. Reports on vascular
smooth muscle cells and endothelial cells provide numerous
indications that store depletion is associated with the acti-
vation or insertion not only of Orai1 channels but also
additional types of Ca
2+-permeable channel that impact on
cytosolic Ca
2+ concentrations directly or indirectly. The
relationship between these channels and Orai1 requires fur-
ther investigation and would benefit from the application of
new technical approaches that provide better resolution in
subcellular space, better information about associations
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better information about activation of the channels in phys-
iological and pathological contexts when Ca
2+ signalling
occurs in three-dimensional structures that are in slow turn-
over (quiescence) or actively remodelling.
An important step in the short term is to better address the
relevance to physiological settings of experimentally in-
duced store depletion events and the SOCE phenomenon.
Several studies suggest that Ca
2+ release is not necessarily
associated with store depletion and thus that a refilling
process may be activated and maintained in the absence of
store depletion. The reported activation of Orai1-dependent
Ca
2+ entry by PDGF or VEGF in the continuous presence of
extracellular Ca
2+ suggests the involvement of Orai1 in
store refilling even when there is little or no store depletion.
If there is indeed such efficient store refilling via Orai1, it
raises questions about the physiological activation mecha-
nism of Orai1 and the appropriateness of considering Orai1
only in terms of the store depletion-activated Orai1–STIM1
I-CRAC complex. Dependence of non-selective cationic
current on Orai1 [103] and the greater effect of Orai1 siRNA
than Synta 66 on vascular smooth muscle cell migration
[59] are suggestive of multiple rather than singular functions
of Orai1. What these other functions are and whether they
arise indirectly through the I-CRAC mechanism remain to
be determined.
One of the most obvious problems in the field is the
apparently conflicting published data sets on the molecular
basis of SOCE. Put simply: Is SOCE mediated by Orai1,
TRPC, other channels, etc., or all of them? How can differ-
ent investigators use apparently similar experimental proto-
cols and end up with such widely differing results and
conclusions (e.g. Orai1 explains all of SOCE and TRPC
none, or vice versa)? It would be helpful if experimental
conditions were standardised. Another way forward would
be to decrease emphasis on the SOCE phenomenon and
focus attention instead on physiological activators of the
channels and studies in physiological conditions. A further
way forward is to accept that multiple channel types can
contribute to SOCE in cells in vitro in planar culture or
suspension but that the physiological relevance of these
contributions depends on the exact cell type and the context.
An intriguing study, for example, suggested the importance
of the TRPC4 channel at the point in time when endothelial
cells make contact [43]. Such a subtle but important effect
would variably contribute to in vitro planar cell culture
studies depending on the confluence of the cells. Also
important in such a situation would be the substrate on
which the cells were grown and placed during experiments.
Additional challenges ahead involve addressing (1)
whether the vascular I-CRAC channel has a distinct molec-
ular component compared with the I-CRAC channel in T
cells, conferring a basis for distinction by pharmacology
and, potentially, therapeutic drugs; (2) the roles of Orai2
and Orai3 in blood vessels (e.g. Is an ARC channel rele-
vant?); and (3) the nature of the down-stream pathways of
Orai1 channels and other channel types contributing to
SOCE (there may be, for example, discrete consequences
of activating Orai1- compared with TRPC1-containing
channels [60]).
The discovery of Orai1 in Tcells has led to an interesting
and lively period of research in the Ca
2+ signalling and
vascular fields. A previously unrecognised channel type of
vascular smooth muscle cells and endothelial cells seems to
have been identified and appears to have important func-
tional consequences that could be relevant and significant
for fundamental understanding and new therapeutic strate-
gies. We are, however, at the beginning of this period of
investigation and there is much still to learn and resolve.
Application of new experimental methods and emphasis on
other types of existing methods will be necessary as the field
progresses.
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